Rich Pharmaceuticals Inc. (fka RCHA)

[stervc]

Key RCHA & WX:NYSE Relationship…

Within the recent news below, RCHA indicates that they have a key relationship with Wuxi Apptec Biopharmaceutical (WX) which trades on the NYSE that is trading at over $40.00+ per share:

http://finance.yahoo.com/news/rich-pharmaceuticals-announces-completion-manufacture-144500701.html
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China. This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323. Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.

WX:NYSE is where RCHA had competed its GMP clinical batch of RP-323 study drug that was manufactured at the WX:NYSE state-of-the-art facility. RCHA is the company that developed the new formulation and all regulatory required testing methods in 2014, but RCHA transferred the proprietary technology ”successfully” to WX:NYSE for the GMP production of RP-323. This is huge.

Also, WX:NYSE is expected to generated approximately $674 Million in Revenues and to deliver profitability in the area of $1.56 to $1.87 EPS (Earnings Per Share) I bring this point up because I am confident that the due diligence for a company of this magnitude believe this much in RCHA, then I must humble myself and any DD that I think is worthy of passing any kind of negative judgment on this company’s future.

http://ir.wuxiapptec.com/phoenix.zhtml?c=212698&p=irol-IRHome

http://ir.wuxiapptec.com/phoenix.zhtml?c=212698&p=irol-newsArticle&ID=2005433
HANGHAI , Jan. 9, 2015 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has updated its 2014 financial guidance. The company expects to achieve total revenues for full-year 2014 of approximately $674 million, compared to previous guidance of $670-672 million. The company expects to achieve diluted EPS of approximately $1.87 (non-GAAP) and approximately $1.56 (GAAP), compared to previous guidance of 1.83-1.86 (non-GAAP) and $1.55-1.58 (GAAP).

v/r
Sterling